Genelux (GNLX) Insider James Tyree Buys 31,566 Shares
James Tyree picked up 31,566 shares of Genelux Corporation on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
James Tyree bought 31,566 shares of Genelux Corporation ($GNLX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GNLX is down 3.6% after 1 week, down 6.9% after 1 month and down 20.1% to date (from the $3.03 close on Jun 16, 2026).
GNLX
Genelux Corporation
Key Points
- James Tyree acquired 31,566 shares of Genelux Corporation (GNLX) on June 16, 2026.
- The stock traded around $2.96 recently, holding above its 52-week low of $2.29.
- Genelux Corporation focuses on oncolytic viral immunotherapies for difficult-to-treat solid tumor types.
Get $GNLX trade alerts by text
We text you when insiders, Congress or big funds trade $GNLX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Genelux Corporation alert may contain errors. Disclosures
James Tyree Buys Shares of Genelux Corporation
James Tyree acquired 31,566 shares of Genelux Corporation (NasdaqCM: GNLX) on June 16, 2026. This purchase represents a notable block of shares for the clinical-stage biopharmaceutical firm, aligning with several other insider transactions executed on the exact same date.
Insider Buying and Selling at Genelux Corporation
The transaction on June 16, 2026, was not an isolated event among company leadership. On that same day, Mary Mirabelli acquired 31,566 shares, and John Smither also picked up 31,566 shares of Genelux Corporation. Both Mirabelli and Smither joined Tyree in expanding their personal stakes by identical share amounts on the same day.
Genelux Corporation Stock Performance
The equity recently traded at $2.96 per share. Over the past year, the shares have moved between a low of $2.29 and a high of $8.54. The 50-day moving average sits at $2.72, while the 200-day moving average rests at $2.93.
About Genelux Corporation
Genelux Corporation develops oncolytic viral immunotherapies aimed at treating aggressive solid tumors. Its lead candidate, Olvi-Vec, is a modified strain of the vaccinia virus studied for ovarian cancer. The firm also utilizes its proprietary CHOICE discovery platform to advance engineered immunotherapeutic candidates.
What's Ahead for GNLX
Market participants often monitor Form 4 disclosures to track how executive and director ownership evolves over time. These filings provide transparency into open-market transactions and equity awards made by company insiders. Further disclosures will show whether additional executives adjust their positions as the clinical-stage biotech continues developing its product pipeline.
Related Filing Alerts
Source: James Tyree's Form 4 filing on $GNLX (Jun 16, 2026). Find the original filing: GNLX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts